Publicaciones en colaboración con investigadores/as de University of Pisa (9)

2021

  1. SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients

    Rheumatology (United Kingdom), Vol. 60, Núm. 6, pp. 2946-2957

  2. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

    The Lancet, Vol. 398, Núm. 10313, pp. 1811-1824

2019

  1. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients

    Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106

  2. The Big Data Sjögren consortium: A project for a new data science era

    Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23

  3. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 5, Núm. 3, pp. 202-207

2018

  1. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529

  2. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

2016

  1. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052

2015

  1. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

    Oncotarget, Vol. 6, Núm. 35, pp. 37269-37280